Imipenem-Cilastatin-Relebactam, the New Go-To for Pneumonia?
TOPLINE: In a multinational phase 3 trial, imipenem-cilastatin-relebactam demonstrated noninferiority to piperacillin-tazobactam in treating critically ill patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial …